Hyperkalaemia for UKMLA and PLAB 1: protect, shift, remove
Hyperkalaemia questions test the order of treatment. First check the result is real (haemolysis or EDTA contamination), then grade it (mild 5.5–5.9, moderate 6.0–6.4, severe 6.5 mmol/L or more), then look at the ECG. With ECG changes, give IV calcium first: it protects the heart but doesn't lower potassium. Then shift potassium into cells with insulin–glucose, remove it with a binder or dialysis, and monitor glucose and potassium.
| Mild · moderate · severe | 5.5–5.9 · 6.0–6.4 · ≥ 6.5 mmol/L |
|---|---|
| Haemolysed or EDTA sample | Pseudohyperkalaemia: repeat |
| K+ ≥ 6.0 mmol/L | Urgent 12-lead ECG |
| Earliest ECG sign | Tall, tented T waves |
| Late ECG signs | Broad QRS, sine wave |
| ECG changes | IV calcium first |
| Calcium gluconate 10% | 30 mL IV over 10 minutes |
| Shift | Insulin 10 units + glucose 25 g |
| Glucose < 7.0 before insulin | 10% glucose 50 mL/h for 5 h |
| Remove | SZC, patiromer, dialysis |
Hyperkalaemia is one of the few emergencies where UK written exams test the order of treatment as much as the treatment itself. The scenario is usually familiar: an older patient on an ACE inhibitor and spironolactone, a new antibiotic, a creatinine that has crept up, a potassium of 6.8 or 7.1 and an ECG with tall, tented T waves. Then come five options that are all genuine treatments for hyperkalaemia. Only one of them is the right thing to do first.
This guide is the long version of HIGH-YIELD 100 · 09/100, the ninth post in our series on the topics UK written exams keep coming back to. It is written for UKMLA AKT candidates, PLAB 1 candidates and UK medical students preparing for finals. Every clinical point was checked in October 2026 against the UK Kidney Association (UKKA) clinical practice guideline Management of hyperkalaemia in adults (2023 update, further updated in July 2026), the Resuscitation Council UK 2025 special circumstances guidance and NICE technology appraisal TA1148 (April 2026).
Is it real? Pseudohyperkalaemia first
Potassium lives inside cells. The intracellular concentration is around 30 times the plasma concentration, so anything that damages or leaks cells after the blood has been taken will push the measured potassium up without the patient's real potassium changing at all. This is pseudohyperkalaemia (or spurious hyperkalaemia), and it is common.
The usual culprits:
- Haemolysis: a difficult draw, a small needle, squirting blood through a needle into the tube, or shaking the sample. Most laboratories flag a haemolysed sample, and exam questions will often tell you.
- EDTA contamination: the purple-topped full blood count tube contains potassium EDTA. Filling it before the biochemistry tube, or decanting between tubes, can carry potassium into the sample. Clues are a very high potassium with a very low calcium.
- Delay or chilling: a sample that sits for hours, or is refrigerated, before it is spun leaks potassium out of the cells. The UKKA guideline specifically notes that pseudohyperkalaemia can follow a long transit time from the community to the laboratory.
- Very high platelet or white cell counts: in thrombocytosis or leukaemia, potassium leaks from those cells as the sample clots.
- Fist clenching or a long tourniquet time, or sampling from an arm with a potassium-containing drip running.
If pseudohyperkalaemia is suspected, the UKKA recommends paired lithium heparin and clotted samples taken from a large vein with gentle technique and analysed promptly.
The practical rule for exams and the wards: an unexpected high potassium in a well patient should be repeated urgently, but treatment is not delayed when the ECG shows hyperkalaemic changes. An abnormal ECG tells you the potassium is real and is already affecting the heart.
How high is it? The UK severity bands
The UKKA guideline grades hyperkalaemia by serum potassium:
- Mild: 5.5–5.9 mmol/L
- Moderate: 6.0–6.4 mmol/L
- Severe: ≥ 6.5 mmol/L
These bands drive the next decisions. The UKKA recommends an urgent 12-lead ECG for any hospitalised patient with a potassium of 6.0 mmol/L or more, and at least continuous cardiac monitoring for a potassium of 6.5 mmol/L or more (or for anyone with ECG changes). Insulin–glucose is recommended for severe hyperkalaemia and suggested for moderate hyperkalaemia.
Severity isn't only about the number. How fast the potassium has risen matters: a patient on haemodialysis who lives at 6.0 may tolerate it, while a rise from 4.5 to 6.5 over a day in acute kidney injury is far more dangerous. That is one reason the ECG matters so much.
What the ECG shows as potassium climbs
High potassium makes the resting membrane potential of cardiac cells less negative. At first this makes repolarisation faster (tall T waves); as it worsens, conduction slows through the atria, the AV node and the ventricles. The changes you need to recognise:
- Tall, narrow, tented T waves: usually the first change.
- Flattened or absent P waves and a prolonged PR interval: atrial conduction is failing.
- Broad QRS complexes and bradycardia: ventricular conduction is slowing. Bradycardia may be the only new change in someone with an already abnormal ECG.
- A sine wave pattern: the broad QRS merges with the T wave. This is a pre-arrest rhythm.
- Cardiac arrest: VF, VT, asystole or PEA. Hyperkalaemia is one of the "Hs" in every UK advanced life support algorithm.
Two pitfalls:
- The changes don't follow a strict order and don't track the potassium level reliably. Some patients have a sine wave at 7.5; others have a normal ECG at 8.0.
- A normal ECG doesn't make a high potassium safe. A potassium of 7.0 with a normal ECG is still severe hyperkalaemia and still needs urgent treatment to lower it. What the normal ECG changes is whether you need calcium.
Step 1: ECG changes? Protect the heart with IV calcium
The UKKA describes the hospital treatment of hyperkalaemia as a logical sequence of steps that you should "never walk away without completing": protect the heart, shift potassium into cells, remove potassium from the body, monitor the potassium and glucose, then prevent it happening again.
Step 1 is IV calcium, for patients with hyperkalaemic ECG changes. The UKKA and Resuscitation Council UK 2025 doses give the same amount of calcium, 6.8 mmol, as either:
- Calcium gluconate 10%: Dose: 30 mL IV over 10 minutes · When: Most patients
- Calcium chloride 10%: Dose: 10 mL IV over 5 minutes · When: Preferred in cardiac arrest or peri-arrest
Calcium chloride contains about three times as much calcium per mL, which is why the volume is a third. It is more irritant to veins, so the UKKA prefers the gluconate salt unless the patient is in or near cardiac arrest. One difference worth knowing: the Resuscitation Council UK 2025 guideline lists calcium chloride first, with gluconate if chloride isn't available. Both give the same 6.8 mmol, so for exams the point that matters is calcium first; you'll rarely be asked to choose between the two salts.
The single most tested fact: calcium does not lower potassium. It antagonises the effect of potassium on the cardiac membrane, steadying the heart and reducing the risk of arrhythmias. The ECG often improves within minutes, but the effect wears off in roughly 30–60 minutes. In those minutes you must start treatment that actually brings the potassium down.
Record a 12-lead ECG before and after treatment so you can see whether the changes have resolved. In July 2026 the UKKA downgraded its IV calcium recommendations from "recommend" to "suggest", reflecting the limited trial evidence rather than a change in practice: calcium for hyperkalaemic ECG changes remains the expected first step in UK emergency departments and in UK exams.
Steps 2 and 3: shift potassium into cells, then remove it
Step 2: shift
Insulin–glucose drives potassium into cells by stimulating the sodium–potassium pump. The UKKA dose is 10 units of soluble insulin in 25 g of glucose by IV infusion. It is recommended for severe hyperkalaemia (≥ 6.5 mmol/L) and suggested for moderate hyperkalaemia (6.0–6.4 mmol/L). The UKKA's lay summary describes insulin–glucose as the most effective emergency treatment for lowering potassium.
Nebulised salbutamol 10–20 mg also shifts potassium into cells, through beta-2 receptors. The UKKA recommends it only as an add-on to insulin–glucose in severe hyperkalaemia, and says it should not be used on its own for severe hyperkalaemia. It may be used as an add-on in moderate hyperkalaemia.
IV sodium bicarbonate is not routinely recommended for acute hyperkalaemia. It has a role in cardiac arrest caused by hyperkalaemia and, as oral treatment, in people with chronic kidney disease and a low bicarbonate, but not as a standard emergency treatment.
Shifting is temporary. Insulin and salbutamol move potassium into cells; they don't take it out of the body. As the effect wears off, the potassium rebounds, typically within a few hours. That is why step 3 can't be skipped.
Step 3: remove
- Potassium binders. The UKKA recommends sodium zirconium cyclosilicate (SZC) in the emergency management of severe hyperkalaemia and suggests it be considered in moderate hyperkalaemia. The UKKA summary table gives the acute dose as 10 g three times a day for up to 72 hours. NICE TA1148 (April 2026) supports SZC "in emergency care for acute life-threatening hyperkalaemia alongside standard care". Patiromer is an alternative binder. Binders exchange potassium in the gut, so they work over hours, not minutes.
- Calcium resonium (calcium polystyrene sulfonate) is no longer routinely used for acute or chronic hyperkalaemia in UK guidance.
- Dialysis. Patients already on haemodialysis with severe hyperkalaemia (K+ ≥ 6.5 mmol/L) should be dialysed urgently, with standard medical treatment if dialysis isn't immediately available, and IV calcium first if there are toxic ECG changes. For other patients, dialysis is considered when severe hyperkalaemia doesn't respond to medical treatment, often alongside severe AKI, acidosis or fluid overload. The timing and type of renal replacement therapy is an urgent renal or critical care decision.
- Treat the cause. Stopping potassium-raising drugs, giving fluids for a pre-renal AKI and relieving urinary obstruction all help the kidneys excrete potassium again.
What happens next in the UK: monitoring, causes and stopping drugs
Watch the glucose
Hypoglycaemia is the commonest harm from hyperkalaemia treatment, and it can happen hours after the insulin has been given. The UKKA recommends checking blood glucose at 0, 30, 60, 90, 120, 180, 240, 300 and 360 minutes (six hours) after insulin–glucose.
If the pre-treatment glucose is below 7.0 mmol/L, start 10% glucose at 50 mL/hour for 5 hours (a further 25 g) after the insulin–glucose to prevent hypoglycaemia. Older patients, people without diabetes and those with lower kidney function are at higher risk, because insulin is cleared by the kidneys.
Recheck the potassium and the ECG
After treating moderate or severe hyperkalaemia, the UKKA suggests checking the serum potassium at least 1, 2, 4, 6 and 24 hours later, both to see whether treatment worked and to catch the rebound. Repeat the 12-lead ECG after treatment. If the potassium is still high, repeat the shifting treatment, keeping a close eye on the glucose, and seek renal advice early.
Find the cause, stop the drug
Most hyperkalaemia in hospital comes from a combination of reduced kidney excretion and a drug that blocks potassium loss:
- Kidney: acute kidney injury and chronic kidney disease.
- Drugs: ACE inhibitors, angiotensin receptor blockers (ARBs), spironolactone and other mineralocorticoid receptor antagonists, amiloride, trimethoprim (it blocks sodium channels in the collecting duct, like amiloride), NSAIDs, potassium supplements, heparin and beta-blockers.
- Hormonal: Addison's disease (mineralocorticoid deficiency), often with hyponatraemia, hypotension and tiredness.
- Release from cells: rhabdomyolysis, tumour lysis syndrome, burns and severe acidosis such as DKA.
The UKKA recommends that ACE inhibitors, ARBs and mineralocorticoid receptor antagonists be withheld during acute illness, and that the risk of recurrence be weighed before they are restarted. It also advises caution with trimethoprim in people with kidney impairment or on these drugs, and recommends sick day advice for people on them. In people with heart failure or chronic kidney disease, these drugs are often lifesaving, so the long-term aim is to restart them once the potassium is controlled, sometimes with a binder. Since July 2026, the UKKA and NICE TA1148 support SZC for persistent hyperkalaemia from a potassium of 5.5 mmol/L in people with CKD stage 3b–5 or heart failure who are not on dialysis, so that RAAS blockers can be kept at an optimised dose.
Try it: an exam-style question
A 74-year-old man has generalised weakness for 2 days and is seen in the Emergency Department. He has heart failure and takes ramipril and spironolactone. He started trimethoprim for a urinary tract infection 4 days ago. He is alert. His temperature is 36.8°C, pulse rate 46 bpm, BP 108/64 mmHg, respiratory rate 16 breaths per minute and oxygen saturation 96% breathing air.
Investigations:
- Potassium 7.1 mmol/L (3.5–5.3), sample not haemolysed
- Sodium 134 mmol/L (135–146)
- Glucose 6.4 mmol/L (4.0–7.8)
- Urea 18.2 mmol/L (2.5–7.8)
- Creatinine 210 micromol/L (60–120); 118 micromol/L 3 months ago
- ECG: tall tented T waves and broad QRS complexes
Which is the most appropriate initial management?
- A. Intravenous 10% calcium gluconate 30 mL
- B. Intravenous soluble insulin 10 units with glucose 25 g
- C. Nebulised salbutamol 20 mg
- D. Oral sodium zirconium cyclosilicate
- E. Repeat potassium on a fresh sample
Decide on your answer before reading on.
Answer: A. Intravenous 10% calcium gluconate 30 mL.
This item tests the order of treatment in severe hyperkalaemia with ECG changes, according to the UK Kidney Association (UKKA) guideline Management of hyperkalaemia in adults (updated July 2026).
The clinical picture
- A potassium of 7.1 mmol/L is severe (6.5 or above). The sample is not haemolysed, and the ECG shows tented T waves, broad QRS complexes and a slow pulse, meaning his heart is already affected.
- The likely cause is an acute kidney injury (creatinine 1.8 times his baseline) in a man taking ramipril, spironolactone and trimethoprim.
Why give calcium first
- With ECG changes, protect the heart first. Give 30 mL of 10% calcium gluconate IV over 10 minutes, or 10 mL of 10% calcium chloride over 5 minutes (UKKA), guided by the setting. He is alert with a reasonable blood pressure, so he is not peri-arrest and calcium gluconate is the usual choice.
- Calcium does not lower his potassium. Give insulin–glucose straight after, and because his glucose is below 7.0 mmol/L, he then needs 10% glucose at 50 mL/hour for 5 hours, with glucose checks for 6 hours.
- After that: a potassium binder, potassium checks at 1, 2, 4, 6 and 24 hours, and stopping all three drugs while the kidney injury is assessed and treated.
How the answer changes when the question is twisted
- The ECG is normal: calcium is not needed, but a potassium of 7.1 mmol/L is still severe and needs urgent treatment to lower it, starting with insulin–glucose.
- He is in cardiac arrest or peri-arrest: 10% calcium chloride 10 mL is preferred.
- His glucose before treatment is 7.0 mmol/L or above: skip the 10% glucose infusion, but still check his glucose.
Why the others are wrong
- B. Intravenous soluble insulin 10 units with glucose 25 g: the most effective way to lower his potassium, and it comes next. But it does not protect the heart, and with ECG changes, protecting the heart comes first.
- C. Nebulised salbutamol 20 mg: an add-on to insulin–glucose only. UK guidance advises against using it alone for severe hyperkalaemia.
- D. Oral sodium zirconium cyclosilicate: removes potassium from the body, but over hours. Give it after protecting the heart and shifting potassium into cells.
- E. Repeat potassium on a fresh sample: reasonable for an unexpected result in a well patient with a normal ECG. Here the ECG changes mean he needs treatment now. Do not wait.
How to revise hyperkalaemia
Hyperkalaemia questions are rarely about a single fact. They test whether you can put the steps in the right order under pressure. A sensible plan:
- Learn the UKKA severity bands and the two ECG thresholds (6.0 for an urgent ECG, 6.5 for continuous monitoring) from this page.
- Say the steps out loud until they are automatic: is it real, how high is it, has the ECG changed, then protect, shift, remove, monitor and prevent.
- Do 15–20 mixed electrolyte questions, timed, and for every hyperkalaemia question write down the step the question is really testing before you look at the options. Read the explanation for every option, not just the one you picked.
- Link it to the drugs. Every time you meet ramipril, losartan, spironolactone or trimethoprim in a question, ask yourself what the potassium is doing.
- Repeat the ones you got wrong three days later.
If you're preparing for the clinical exams too, hyperkalaemia appears in acute medicine and prescribing stations, where you have to manage it step by step and explain your plan to an examiner. OSCE Revisions has full stations for PLAB 2, UKMLA CPSA and AMC Clinical, with AI patients and examiner-style marking.
Educational content for exam preparation, based on the UK Kidney Association hyperkalaemia guideline (updated July 2026), Resuscitation Council UK 2025 guidance and NICE TA1148. It is not individual medical advice. Always follow your local guidelines in practice.
Questions
What potassium level is severe hyperkalaemia in the UK?
The UK Kidney Association defines mild hyperkalaemia as 5.5–5.9 mmol/L, moderate as 6.0–6.4 mmol/L and severe as 6.5 mmol/L or more.
Does calcium gluconate lower potassium?
No. IV calcium protects the heart by stabilising the cardiac membrane, usually within minutes, but it doesn't change the serum potassium. Its effect lasts about 30–60 minutes, so insulin–glucose and a binder must follow.
What is the dose of calcium gluconate for hyperkalaemia?
UKKA and Resuscitation Council UK guidance give 30 mL of 10% calcium gluconate IV over 10 minutes, or 10 mL of 10% calcium chloride over 5 minutes (preferred in cardiac arrest or peri-arrest), for patients with hyperkalaemic ECG changes.
What is the insulin–glucose regimen for hyperkalaemia?
10 units of soluble insulin in 25 g of glucose IV. Check the glucose at 0, 30, 60, 90, 120, 180, 240, 300 and 360 minutes, and if the glucose was below 7.0 mmol/L before treatment, give 10% glucose at 50 mL/hour for 5 hours.
What causes pseudohyperkalaemia?
Haemolysis, EDTA contamination from the full blood count tube, delayed or chilled samples, very high platelet or white cell counts, fist clenching and a long tourniquet time. Repeat an unexpected result, but don't delay treatment if the ECG has changed.
Which drugs cause hyperkalaemia?
ACE inhibitors, ARBs, spironolactone and other mineralocorticoid receptor antagonists, amiloride, trimethoprim, NSAIDs, potassium supplements, heparin and beta-blockers. The risk is highest when they are combined, or given during an acute kidney injury.
Sources
- UK Kidney Association: Management of hyperkalaemia in adults (updated July 2026)
- UK Kidney Association: Management of hyperkalaemia in adults (December 2023)
- Resuscitation Council UK: 2025 special circumstances guidelines
- NICE TA1148: sodium zirconium cyclosilicate for treating hyperkalaemia
- Patient.info Professional: hyperkalaemia
- University Hospitals of Leicester: hyperkalaemia guideline
Reviewed by the MedRevisions clinical team
Last reviewed